Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review

Raquel Sanabria- de la Torre, Sheila González-Salvatierra, Cristina García-Fontana (), Francisco Andújar-Vera, Beatriz García-Fontana (), Manuel Muñoz-Torres and Blanca Riquelme-Gallego
Additional contact information
Raquel Sanabria- de la Torre: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Sheila González-Salvatierra: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Cristina García-Fontana: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Francisco Andújar-Vera: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Beatriz García-Fontana: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Manuel Muñoz-Torres: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain
Blanca Riquelme-Gallego: Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain

IJERPH, 2022, vol. 19, issue 23, 1-14

Abstract: Sclerostin is most recognized for its role in controlling bone formation; however, it is also expressed in the heart, aorta, coronary, and peripheral arteries. Human studies have associated high circulating sclerostin levels with the presence of different cardiovascular diseases (CVD), surrogate CVD markers, and a high risk of cardiovascular events in some populations. However, this is still a matter of scientific debate, as the results have been very heterogeneous among studies. In the present review, the association between serum sclerostin levels and CVD and/or cardiovascular mortality was analyzed. For this purpose, a scoping review was performed in which articles measuring serum sclerostin levels and cardiovascular risk in patients were selected. Eleven articles answered the research question; of these articles, 8/11 evaluated the association between sclerostin and CVD, of which 4/8 found a positive association, 2/8 found a negative association, and 2/8 found no association between variables. Five (5/11) of the articles included in the study evaluated cardiovascular mortality, of which 3/5 found a positive association, 1/5 found a negative association, and 1/5 found no association between variables. In conclusion, we did not find sufficient results to be able to demonstrate an association between elevated sclerostin levels and the development of CVD and/or cardiovascular mortality in the general population due to heterogeneity in the results. However, there seems to be a tendency to consider increased sclerostin levels as a risk factor for both the development of cardiovascular events and cardiovascular mortality in specific populations. Further studies in this field will help to solve some of the inconsistencies found during this scoping review and allow for the future use of sclerostin measurement as a strategy in the prevention and diagnosis of CVD and/or cardiovascular mortality.

Keywords: biomarkers; cardiovascular disease; cardiovascular mortality; cardiovascular risk; sclerostin (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/23/15981/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/23/15981/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:23:p:15981-:d:988876

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().